Hemorrhagic stroke

Investor call to feature presentations from Leslie Lucien Citrome, MD, MPH, Issam Awad, MD, FACS and Connie Lee, PsyD SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Neurelis, Inc. today announced it will host an investor call to highlight updates on two of its neuroscience product development candidates, NRL-1004 for acute agitation episodes and NRL-1049 for cerebral cavernous malformations (CCMs). The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET. To register, click here. Agenda Topics NRL-1004 for Acute Agitation Episodes – 10:30 am - 11:15 am ET NRL-1004, an investigational nasal spray formulation of olanzapine and Neurelis proprietary Intravail® technology, for the treatment of acute agitation episodes, featuring Leslie Lucien Citrome, MD, MPH (New York Medical College, SUNY Upstate Medical University, Icahn School of Medicine at Mount Sinai). NRL-1049 for Cerebral Cavernous Malformations – 11:15 am - 12:00 pm ET NRL-1049, an investigational, Phase 1, new chemical entity, Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMs), featuring Issam Awad, MD, MSc, FACS, MA (University of Chicago Medicine) and Connie Lee, PsyD (Alliance to Cure Cavernous Malformation) Presentations will include overviews of the disease state, unmet need, and current treatment landscape for patients, as well as a discussion of the potential differentiating features of Neurelis' product candidates. A live question and answer session will follow the formal presentations of both segments. About Leslie Lucien Citrome, MD, MPH Leslie Lucien Citrome, MD, MPH is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, Clinical Professor of Psychiatry at SUNY Upstate Medical University, and Adjunct Clinical Professor of Psychiatry, Icahn School of Medicine at Mount Sinai in New York City, New York. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American Society of Clinical Psychopharmacology where he currently serves as Immediate Past-President. In addition to his academic positions, he has a private practice in psychiatry in Pomona, New York and is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. Dr. Citrome obtained his MD degree from the McGill University Faculty of Medicine in 1983 and his MPH degree from the Columbia School of Public Health in 1996. His immediate prior position was as the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, where he worked from 1994 through 2010 and achieved the rank of Professor of Psychiatry at the New York University School of Medicine. Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of number needed to treat and number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australasia. His main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is author or coauthor of over 600 research reports, reviews, and chapters in the scientific literature. He is a member of the Board of Directors of the World Association of Medical Editors. Dr. Citrome is editor-in-chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis, editor emeritus, International Journal of Clinical Practice where he was editor-in-chief 2013-2019; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; section editor for psychopharmacology for Current Psychiatry; and also serves as an editorial board member for several other medical journals. About Issam Awad, MD, FACS Issam Awad, MD, MSc, FACS, MA is the John Harper Seeley Professor of Neurological Sciences at the University of Chicago. He leads the Neurovascular Surgery Program, co-leads the Stroke and Neurovascular Care team at UChicago Medicine, and Directs of the Safadi Program of Excellence in Clinical and Translational Neuroscience and the first accredited Center of Excellence for Cerebral Cavernous Malformations (CCM) in the U.S. His research focuses on vascular biology, genetics and comprehensive outcome analysis in neurovascular disease and stroke, and his active projects include National Institutes of Health and department of Defense funded investigations of molecular mechanisms involved in the formation and progression of cerebrovascular malformations. Additionally, he leads several clinical trials on minimally invasive techniques for surgical treatment of hemorrhagic stroke and novel drug therapies for Cavernous Angiomas with Symptomatic Hemorrhage (CASH). Dr. Awad's scientific innovations include the characterization of subcortical ischemic lesions in the aged, advances in the understanding of the natural history and biologic behavior of cerebral vascular malformations and numerous technical advances in neurovascular and epilepsy surgery. He has authored leading textbooks and published more than 350 scholarly papers related to clinical innovations, surgical outcomes and research. He has also served as president of the Congress of Neurological Surgeons, chairman of the Cerebrovascular Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons, and on the executive committee of the American Stroke Association and the board of governors of the American College of Surgeons. He served on the U.S. National Council for Neurological Disorders and Stroke and is the founding chairman of the Scientific Advisory Board of the Alliance to Cure Cavernous Malformation. About Connie Lee, PsyD Connie Lee, PsyD is the founding President of the Alliance to Cure Cavernous Malformation. Connie is a licensed clinical psychologist and the mother of a daughter with multiple cavernous malformations. Connie's personal story with cavernous malformation began in January 2000. At that time, Connie's 4-month-old daughter Julia received brain surgery for a major hemorrhage and hydrocephalus caused by a cavernous malformation. Dr. Lee founded Angioma Alliance, the original name of the Alliance to Cure, in 2002. She has guided the organization from its beginnings as a support group to its current role as the driving force for research, legislation, and patient care. About Neurelis Neurelis, Inc., is a neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical needs. In 2020, the FDA approved Neurelis' VALTOCO® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from an individual's usual seizure pattern in adult and pediatric patients 6 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL®. For more information on VALTOCO, please visit . For more information on Neurelis. please visit . For the latest scientific information on VALTOCO, please visit . Contacts: Neurelis: Brittany Bradrick, Chief Operating Officer and Chief Financial Officer, +1 858 251 2100 Media: Glenn Silver, FINN Partners, +1 646 871 8485

BOSTON, Feb. 7, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that Dr. Pedro Lylyk, Director General of ENERI, will deliver a symposium presentation entitled, "Endovascular Shunting for Hydrocephalus After Subarachnoid Hemorrhage and Other Applications," at the International Stroke Conference in Phoenix, Arizona on Wednesday, February 7th. Dr. Lylyk, principal investigator for multiple studies of the eShunt System, and the first in the world to place the eShunt device, stated, "I am looking forward to sharing with this important international audience the tremendous experience we have had with the eShunt System, and its novel endovascular solution to treat a non-vascular problem." Dan Levangie, CereVasc President & CEO stated, "Hemorrhagic stroke remains a significant global health issue and can be further complicated by the development of hydrocephalus. We are honored to have clinical results with the eShunt System highlighted and presented by Dr. Lylyk at the International Stroke Conference this week during the Cerebrovascular Education and Discovery session, as we believe the eShunt System has great potential to contribute to better stroke care." About CereVasc, Inc. Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating hydrocephalus (CH), a potential improvement to the current standard of care. The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Cerebrovascular and Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebral spinal fluid (CSF) shunt and delivery components, which are designed to treat CH without invasive surgery. For additional information, please visit our website at . The eShunt® Device is an investigational device and not available for sale within or outside the United States. Company Contacts: DJ Cass CereVasc, Inc. [email protected] SOURCE CereVasc, Inc.

Data-heavy presence at the International Stroke Conference validates RapidAI as the clear choice in clinical AI for stroke care SAN MATEO, Calif.--(BUSINESS WIRE)-- RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, will showcase its clinical expertise and industry-leading innovation at the American Heart Association’s International Stroke Conference (ISC) in Phoenix, AZ, February 7-9. Through various research presentations, poster abstracts, and learning sessions, RapidAI will highlight how its AI platform is reshaping the industry and driving confident, efficient, and accessible patient care. “Our commitment to research and finding new, improved ways to enhance patient outcomes is a core pillar for us,” said Dr. David Stoffel, chief business officer of RapidAI. “Our dedication to enabling clinical excellence in stroke care has never been stronger, and the data that will be unveiled at ISC serves as yet another proof point in how we continuously push the envelope to expand access to better stroke care.” RapidAI-Related Live Sessions and Events at ISC: February 7, 2024 Learning Studio: The Practical Use of AI in Building a Stroke Program, Gregory Albers, M.D., and Vivek Yedavalli, M.D., M.S. February 7, 12:45 - 1:15 PM MST at Learning Studio 1 Satellite Symposium: The Frontier of Stroke Diagnosis (RapidAI): How Can Artificial Intelligence Improve Acute Stroke Care for Ischemic and Hemorrhagic Stroke?, Gregory Albers, M.D., as a part of EMCREG-International’s Satellite Symposium, ‘Optimizing Critical Care for Intracranial Hemorrhage: Impact of Anticoagulation Reversal, Care Building, and Artificial Intelligence on Outcome’ February 7, 6:00 - 7:30 PM MST at Hyatt Regency Phoenix, Phoenix Ballroom, 2nd Floor Poster Presentation: Detecting MeVOs and Collateral Assessment with Multimodality AI Approach, Mahdi Sowlat, M.D. February 7, 6:25 - 6:30 PM MST at Poster Hall, Halls 5-6 February 8, 2024 Late-Breaking Science Oral Abstracts IV: Subgroup Analyses From the TIMELESS Trial, Gregory Albers, M.D. February 8, 4:06 - 4:18 PM MST at North 121 A-C Poster Presentation: Acute Ischemic Stroke Patients After Implementation of the RapidAI Platform in a Comprehensive Stroke Center in Santiago, Chile, Pablo Lavados, M.D., presented by Greg Albers, M.D. February 8, 6:00 - 7:00 PM MST at Poster Hall, Halls 5-6 Presentation and Networking Event: AI Beyond the Algorithm, Dan Gibson, M.D. February 8, 6:00 - 8:00 PM MST at the Croft Downtown RapidAI-hosted event with clinical insights, networking opportunities, and live demo stations For more about RapidAI’s ISC presence, including presentations and 11 posters being showcased, please visit us at ISC Booth #805 or find the full schedule of sessions and more here. About RapidAI RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from 12 million scans in more than 2,200 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI – where AI meets patient care.